Collaboration validates, diversifies and further strengthens CureVac’s RNActive® technology platform
Story content courtesy of CureVac GmbH and b3 Newswire, DE
The research proposal selected by DARPA involves collaboration among CureVac, Sanofi Pasteur (including Sanofi Pasteur VaxDesign Corp.) and In-Cell-Art S.A.S., a French biotech company contributing its nanoparticle technology. In this 4-year project, CureVac and the others will further advance key aspects of CureVac’s RNActive® technology platform and will evaluate several vaccine candidates in a number of relevant disease models.
Parallel to the collaboration agreements, CureVac and Sanofi Pasteur have also signed an option agreement with pre-agreed license terms for several pre-defined pathogens. “The opportunity to collaborate with a world-leading vaccine company such as Sanofi Pasteur is an exciting step as we continue to demonstrate in both the commercial and defense-related settings the broad applicability and versatility of our RNActive® technology platform, which may become game changing for the vaccine field,” adds Karl-Josef Kallen, Head of R&D at CureVac.
